Literature DB >> 16503203

Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer.

Susumu Sakata1, Djamel Lebeche, Yuri Sakata, Naoya Sakata, Elie R Chemaly, Li Fan Liang, Prabhu Padmanabhan, Noboru Konishi, Miyako Takaki, Federica del Monte, Roger J Hajjar.   

Abstract

The Otsuka-Long-Evans Tokushima Fatty rat represents a model for spontaneous non-insulin-dependent type II diabetes mellitus (DM), characterized by diastolic dysfunction and associated with abnormal calcium handling and decrease in sarcoplasmic reticulum Ca2+ -ATPase (SERCA2a) expression. The aim of this study was to examine whether SERCA2a gene transfer can restore the energetic deficiency and left ventricular (LV) function in this model. DM rats were randomized to receive adenovirus carrying either the SERCA2a gene (DM + Ad.SERCA2a) or the beta-galactosidase gene (DM + Ad.betaGal) or saline (DM + saline). LV mechanoenergetic function was measured in cross-circulated heart preparations 3 days after infection. In DM, end-systolic pressure at 0.1 ml intraballoon water (ESP0.1) was low and end-diastolic pressure at 0.1 ml intraballoon water (EDP0.1) was high (22 mm Hg), compared with non-DM (EDP0.1 12 mm Hg). In DM + Ad.SERCA2a, however, ESP0.1 was increased over 200 mm Hg and EDP(0.1) was decreased to 7 mm Hg. LV relaxation rate was fast in DM + Ad.SERCA2a, but slow in the other DM groups. There was no difference in relation between cardiac oxygen consumption per beat and systolic pressure-volume area among all groups. Finally, the oxygen cost of LV contractility in DM was about three times as high as that of normal. In DM + Ad.SERCA2a, the oxygen cost decreased to control levels, but in DM + Ad.betaGal/DM + saline it remained high. In DM failing hearts, the high oxygen cost indicates energy wasting, which contributes to the contractile dysfunction observed in diabetic cardiomyopathy. SERCA2a gene transfer transforms this inefficient energy utilization into a more efficient state and restores systolic and diastolic function to normal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503203     DOI: 10.1016/j.ymthe.2006.01.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  22 in total

Review 1.  Diabetic cardiomyopathy: signaling defects and therapeutic approaches.

Authors:  Joseph S Dobrin; Djamel Lebeche
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-03

2.  SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells.

Authors:  Lahouaria Hadri; Regis Bobe; Yoshiaki Kawase; Dennis Ladage; Kiyotake Ishikawa; Fabrice Atassi; Djamel Lebeche; Evangelia G Kranias; Jane A Leopold; Anne-Marie Lompré; Larissa Lipskaia; Roger J Hajjar
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

3.  Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins.

Authors:  Susumu Sakata; Djamel Lebeche; Naoya Sakata; Yuri Sakata; Elie R Chemaly; Li Fan Liang; Tsuyoshi Tsuji; Yoshiaki Takewa; Federica del Monte; Richard Peluso; Krisztina Zsebo; Dongtak Jeong; Woo Jin Park; Yoshiaki Kawase; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2007-01-10       Impact factor: 5.000

4.  Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes.

Authors:  Véronique A Lacombe; Serge Viatchenko-Karpinski; Dmitry Terentyev; Arun Sridhar; Sitaramesh Emani; John D Bonagura; David S Feldman; Sandor Györke; Cynthia A Carnes
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-08-29       Impact factor: 3.619

5.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 6.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Human Cardiac Gene Therapy.

Authors:  Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367

Review 8.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

9.  Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy.

Authors:  Jorge Suarez; Brian Scott; Wolfgang H Dillmann
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-09-17       Impact factor: 3.619

10.  Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a.

Authors:  Ioannis Karakikes; Maengjo Kim; Lahouaria Hadri; Susumu Sakata; Yezhou Sun; Weijia Zhang; Elie R Chemaly; Roger J Hajjar; Djamel Lebeche
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.